Skip to content
lifestyle.womensconference.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
OncoC4
OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors
October 19, 2026
OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody
September 16, 2026
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
September 1, 2026
OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
August 18, 2026